Faeth Therapeutics (FTH) Cash from Financing Activities (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Cash from Financing Activities came in at $185.8 million in Q1 2026, up 86934.58% YoY from N/an in Q1 2025, and up 167510.81% on a QoQ basis from -$111000.0 in Q4 2025.
Faeth Therapeutics (FTH) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Cash from Financing Activities data on file, last reported at $185.8 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 86934.58% year-over-year to $185.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.4 million (up 23508.46% YoY) and the FY2025 annual result came in at -$645000.0, up 18.04% from the prior year.
- Cash from Financing Activities improved to $185.8 million in Q1 2026, from -$111000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $185.8 million in Q1 2026 to a low of -$7.9 million in Q2 2023.
- A 5-year average of $11.5 million and a median of -$194000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 320.17% — and 2026, when it surged 86934.58%.
- Tracing FTH's Cash from Financing Activities over 5 years: stood at -$124000.0 in 2022, then slumped by 247.58% to -$431000.0 in 2023, then jumped by 54.99% to -$194000.0 in 2024, then jumped by 42.78% to -$111000.0 in 2025, then soared by 167510.81% to $185.8 million in 2026.
- The last three Cash from Financing Activities figures came in at $185.8 million (Q1 2026), -$111000.0 (Q4 2025), and -$152000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | -1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.68 Mn |
| Jun 30, 2026 | -1.68 Mn |
| Mar 31, 2026 | 185.83 Mn |
| Mar 31, 2026 | 185.83 Mn |
| Dec 31, 2025 | -111,000.00 |
| Dec 31, 2025 | -111,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | -168,000.00 |
| Jun 30, 2025 | -168,000.00 |
| Mar 31, 2025 | -214,000.00 |
| Mar 31, 2025 | -214,000.00 |
| Dec 31, 2024 | -194,000.00 |
| Dec 31, 2024 | -194,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -209,000.00 |
| Mar 31, 2024 | -209,000.00 |